cureVision continues to scale

The medical technology startup cureVision, a pioneer in the field of AI-supported medical imaging, has successfully completed its current financing round. The fresh capital comes from the Companisto Business Angel Network, Brandenburg Kapital, BioLab Holdings Inc. (USA) and other co-investors.

cureVision intends to use the financing to further develop its AI technology for fully automated 3D wound measurement with integrated bacterial scanning, expand its sales structure and drive forward preparations for its US market entry in 2026.

Automated 3D wound measurement as a driver of innovation

The start-up is based in Potsdam and develops AI-supported imaging systems for medical diagnostics. cureVision has developed a technology that enables medical professionals to measure chronic and acute wounds precisely, contactlessly and in real time. The integrated bacterial scan provides additional information about possible infections and thus facilitates clinical decision-making.

Our mission is to make next-generation medical imaging available worldwide. With the support of our investors, we are ideally positioned to scale internationally and push for FDA approval in the US.

Richard Fobo, CEO and co-founder of cureVision

The solution is designed to save time in day-to-day care, improve documentation quality and optimize care outcomes for patients.

Strong investor structure and strategic support

With Brandenburg Kapital, a subsidiary of the Investitionsbank des Landes Brandenburg (ILB), cureVision has gained an experienced partner that has already supported numerous deeptech and healthtech companies in the region.

We see great potential in cureVision's technology and look forward to supporting the next phase of growth - especially as the company scales its sales structure out of Brandenburg.

Thomas Krause, Managing Director of Brandenburg Kapital

Companisto, a European network for business angel syndication, has also been one of the first supporters."The startup and the team impress with their technological depth and clear market vision," explains Andreas Fakler, Investment Director at Companisto. The new investor BioLab Holdings Inc. from Phoenix, Arizona, also sees international growth potential: "We see a high demand for the cureVision solution in the USA and will prepare the market entry together".

Awards and recognition

cureVision has received several awards for its work, including the Health-i Award, the Novartis Digital Health Prize, the Eugen Münch Prize from the Röhn Foundation, the Bavarian Innovation Prize and the German Health Award.

With the completion of the financing round, cureVision is now focusing on scaling its sales activities in Germany and Europe and on the planned market entry in the USA in 2026. At the same time, the AI platform will be further expanded to open up additional clinical indications and integration options in hospital information systems (HIS).